InDex Pharmaceuticals strengthens the organization with Eva Arlander as Chief Development Officer and announces changes in the composition of the management team

May 2, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Eva Arlander as Chief Development Officer. Eva will also be part of the management team, together with acting Chief Executive Officer and Chief Financial Officer Johan Giléus, Chief Medical Officer Anders Bröijersén and Chief Scientific Officer Charlotte Admyre.

Peter Zerhouni steps down as CEO of InDex Pharmaceuticals

April 11, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that after more than seven years as CEO, Peter Zerhouni has decided to leave his position. The company’s CFO Johan Giléus has been appointed acting CEO while a new CEO is being recruited, and he will also continue as CFO.

InDex Pharmaceuticals prepares for commercialisation of cobitolimod

March 13, 2022 – InDex Pharmaceuticals Holding AB (publ) is planning for self-commercialisation of the drug candidate cobitolimod in the US with strategic collaborations in other regions. Launch is expected in 2027, with the potential for annual sales to reach more than USD 1 billion, in moderate to severe left-sided ulcerative colitis. An in-depth presentation of the strategy and market potential, together with the execution of the phase III study CONCLUDE with cobitolimod will be provided at InDex’s Capital Markets Day, tomorrow March 14, 15.00-17.00 CET.

COO Pernilla Sandwall is leaving InDex Pharmaceuticals for a CEO position

February 13, 2022 – InDex Pharmaceuticals Holding AB (publ) today announced that Chief Operating Officer Pernilla Sandwall has decided to leave the company to become CEO of WntResearch. She will continue in her current role until the end of April. The process to recruit her successor will be initiated immediately.

Investor contact

Johan Giléus
Johan Giléus
+46 8 122 038 50